Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

Journal of Virology

Volumn 86, Issue 5, 2012, Pages 2696-2705

  Quashie, Peter K ^a,b   Mesplède, Thibault ^a   Han, Ying Shan ^a   Oliveira, Maureen ^a   Singhroy, Diane N ^a,c   Fujiwara, Tamio ^d   Underwood, Mark R ^e   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d SHIONOGI AND CO LTD   (Japan)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; MK 2048; RALTEGRAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO SELECTION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; SITE DIRECTED MUTAGENESIS; VIRUS DNA CELL DNA INTERACTION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RECOMBINANT;

CELL LINE; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863393356     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06591-11     Document Type: Article

References (77)

1. Adachi A, et al. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Bar-Magen T, et al. 2010. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS 24:2171-2179.
3. Bar-Magen T, et al. 2010. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 84:9210-9216.
4. Bar-Magen T, et al. 2009. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology 6:103.
5. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. 2011. HIV-1 integrase inhibitor resistance and its clinical implications. J. Infect. Dis. 203:1204-1214.
6. Brenner BG, et al. 2011. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J. Med. Virol. 83:751-759.
7. Bukrinsky MI, et al. 1993. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc. Natl. Acad. Sci. U. S. A. 90:6125-6129.
8. Chen JC, et al. 2000. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. U. S. A. 97:8233-8238.
9. Cherepanov P, Maertens GN, Hare S. 2011. Structural insights into the retroviral DNA integration apparatus. Curr. Opin. Struct. Biol. 21:249-256.
10. Cohen C, et al. 2011. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25:F7-F12.
11. Cooper DA, et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
12. DeJesus E, et al. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
13. Derdeyn CA, et al. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
14. Dobard CW, Briones MS, Chow SA. 2007. Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J. Virol. 81:10037-10046.
15. Dolan J, Chen A, Weber IT, Harrison RW, Leis J. 2009. Defining the DNA substrate binding sites on HIV-1 integrase. J. Mol. Biol. 385:568-579.
16. Donahue DA, et al. 2010. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob. Agents Chemother. 54:1047-1054.
17. Eron JJ, et al. 2010. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia(SWITCHMRK1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 375:396-407.
18. Espeseth AS, et al. 2000. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U. S. A. 97:11244-11249.
19. Goethals O, et al. 2008. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 82:10366-10374.
20. Goethals O, et al. 2011. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a secondgeneration HIV-1 integrase inhibitor. Antiviral Res. 91:167-176.
21. Goethals O, et al. 2010. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to firstgeneration integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 402:338-346.
22. Grandgenett DP, Goodarzi G. 1994. Folding of the multidomain human immunodeficiency virus type-I integrase. Protein Sci. 3:888-897.
23. Grinsztejn B, et al. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269.
24. Grobler JA, et al. 2002. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U. S. A. 99:6661-6666.
25. Hare S, et al. 2009. Structural basis for functional tetramerization of lentiviral integrase. PLoS Pathog. 5:e1000515.
26. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236.
27. Hare S, et al. 2011. Structural and functional analyses of the secondgeneration integrase strand transfer inhibitor dolutegravir (S/ GSK1349572). Mol. Pharmacol. 80:565-572.
28. Hazuda DJ, et al. 2004. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. U. S. A. 101:11233-11238.
29. Hazuda DJ, Hastings JC, Wolfe AL, Emini EA. 1994. A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res. 22:1121-1122.
30. Jayappa KD, Ao Z, Yang M, Wang J, Yao X. 2011. Identification of critical motifs within HIV-1 integrase required for importin alpha3 interaction and viral cDNA nuclear import. J. Mol. Biol. 410:847-862.
31. Johnson VA, et al. 2010. Update of the drug resistance mutations in HIV-1: December 2010. Top. HIV Med. 18:156-163.
32. Jones G, et al. 2007. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303), abstr. 627. 14th CROI, Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA.
33. Kobayashi M, et al. 2011. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55:813-821.
34. Krishnan L, et al. 2010. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc. Natl. Acad. Sci. U. S. A. 107: 15910-15915.
35. Lennox JL, et al. 2010. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immune Defic. Syndr. 55:39-48.
36. Low A, et al. 2009. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob. Agents Chemother. 53:4275-4282.
37. Lusso P, et al. 1995. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4 T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-linetropic HIV-1. J. Virol. 69:3712-3720.
38. Lutzke RA, Vink C, Plasterk RH. 1994. Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res. 22:4125-4131.
39. Maertens GN, Hare S, Cherepanov P. 2010. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 468: 326-329.
40. Maignan S, Guilloteau JP, Zhou-Liu Q, Clement-Mella C, Mikol V. 1998. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 282:359-368.
41. Marinello J, et al. 2008. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47:9345-9354.
42. Markowitz M, et al. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
43. McColl D. J, et al. 2007. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase 2 study of elvitegravir (GS-9137), abstr. 9. 16th International HIV Drug Resistance Workshop, Barbados, West Indies.
44. Métifiot M, et al. 2011. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 25:1175-1178.
45. Min S, et al. 2011. Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 25:1737-1745.
46. Min S, et al. 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54:254-258.
47. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. 2010. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist. Updat. 13:139-150.
48. National Committee for Clinical Laboratory Standards. 1979. NCCLS standard. National Committee for Clinical Laboratory Standards, Villanova, PA.
49. Nguyen BY, et al. 2011. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann. N. Y. Acad. Sci. 1222: 83-89.
50. Nishitsuji H, et al. 2009. Augmentation of reverse transcription by integrase through an interaction with host factor, SIP1/Gemin2 is critical for HIV-1 infection. PLoS One 4:e7825.
51. Oliveira M, Brenner BG, Wainberg MA. 2009. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol. Biol. 485:427-433.
52. Oz I, Avidan O, Hizi A. 2002. Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases. Biochem. J. 361:557-566.
53. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 83:8289-8292.
54. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72: 2855-2864.
55. Prlic A, et al. 2010. Pre-calculated protein structure alignments at the RCSB PDB website. Bioinformatics 26:2983-2985.
56. Roy A, Kucukural A, Zhang Y. 2010. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5:725-738.
57. Sato A, et al. 2009. In vitro passage of drug resistant HIV-1 against a next generation integrase inhibitor (INI), S/GSK1349572, abstr. H-932. 49th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC), San Francisco, CA.
58. Schader SM, Colby-Germinario SP, Schachter JR, Xu H, Wainberg MA. 2011. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS 25:1585-1594.
59. Seki T, et al. 2010. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones, abstr. 555. 17th CROI, Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
60. Shimura K, et al. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82:764-774.
61. Song I, et al. 2011. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob. Agents Chemother. 55:3517-3521.
62. Steigbigel RT, et al. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
63. Steigbigel RT, et al. 2010. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin. Infect. Dis. 50:605-612.
64. Summa V, et al. 2008. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51:5843-5855.
65. Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82:12585-12588.
66. Turner D, Wainberg MA. 2006. HIV transmission and primary drug resistance. AIDS Rev. 8:17-23.
67. Van Wesenbeeck L, et al. 2011. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob. Agents Chemother. 55:321-325.
68. Vavro C, et al. 2010. Polymorphisms at position 101 and 124 in the HIV-1 integrase (IN) gene: lack of effects on susceptibility, abstr. H-935. 50th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC), Boston, MA.
69. Wainberg MA. 2004. HIV-1 subtype distribution and the problem of drug resistance. AIDS 18(Suppl 3):S63-S68.
70. Wainberg MA, Zaharatos GJ, Brenner BG. 2011. Development of antiretroviral drug resistance. N. Engl. J. Med. 365:637-646.
71. Walker JM. 2005. The proteomics protocols handbook. Humana Press, Totowa, NJ.
72. Wang JY, Ling H, Yang W, Craigie R. 2001. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 20:7333-7343.
73. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
74. Wilkinson TA, et al. 2009. Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J. Biol. Chem. 284: 7931-7939.
75. Xu HT, et al. 2011. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J. Virol. 85:11300-11308.
76. Zhang ZR, et al. 2003. Fluorescent microplate-based analysis of protein-DNA interactions. I. Immobilized protein. Biotechniques 35:980-982, 984, 986.
77. Zolopa AR, et al. 2010. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J. Infect. Dis. 201:814-822.